Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

Inclusion Criteria10

• Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
• Patients with advanced/metastatic NSCLC
• Must be immunotherapy naive
• Males and females age ≥ 18 years
• ECOG Performance Status 0 - 2
• Measurable disease by RECIST 1.1
• Must have a lesion (either primary or metastatic lesion) that can be safely biopsied to have sufficient tissue (at minimum, 3-4 cores using 20g or larger core biopsy) to generate tumoroids
• Must have at least one target lesion to evaluate treatment response
• Will be receiving anti-PD-1/L1 with or without anti-CTLA-4 per standard of care Adequate organ function defined per standard of care in this setting.
• Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception as required/recommended by each immune checkpoint inhibitor used in the setting of standard of care.